WASHINGTON DC—A new blood test has detected drug-resistant mutations reliably in patients with gastrointestinal stromal tumour (GIST) helping to guide therapy when first-line drugs had failed. This was in a study using the recently approved agent regorafenib. Dr George Demetri of the Dana-Farber Harvard Cancer Center presented findings from the GRID study during the 2013 conference of the American Society for Cancer Research. He told Peter Goodwin why the blood test did better than biopsy testing and about the prospects of treating refractory GIST with rogarafenib.
You may also like...
Low risk localized prostate cancer: no harm from waiting! 16 Mar, 2013 Breast Lumps Between Mammography Visits Signal High Risk 19 Apr, 2018 Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer 11 Oct, 2018 Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer 16 Nov, 2007
- Previous story Gene expression and molecular pathways guide head and neck cancer therapies
- Next story Treatment “holidays” to overcome resistance in advanced melanoma?
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014